FDA PMA
FDA Class 3
Approved
🇺🇸 United States
Kit, Dna Detection, Human Papillomavirus
PMA: P160037
·
Supplement: S019
·
Decision Apr 18, 2024
Classifications
1
FEI Numbers
12
Registration Numbers
12
Basic Information
- Device Name
- Kit, Dna Detection, Human Papillomavirus
- Trade Name
- BD Onclarity HPV Assay
- PMA Number
- P160037
- Supplement Number
- S019
- Device Class
- FDA Class 3
- Product Code
- MAQ
- Generic Name
- KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS
- Medical Specialty
- Unknown
- Advisory Committee
- Microbiology
- Decision
- Approved
- Decision Code
- APPR
- Decision Date
- April 18, 2024
- Date Received
- January 31, 2024
- Supplement Type
- Real-Time Process
- Supplement Reason
- Change Design/Components/Specifications/Material
- Expedited Review
- N
Advisory Committee Statement
Approval for software modifications to the BD Onclarity HPV Assay to allow laboratorians/laboratory sites the ability to access Ct values for internal assay controls and positive clinical samples.
Classifications
This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| MAQ | Kit, Dna Detection, Human Papillomavirus | FDA class 3 | Unknown |